In vivo evolution of antibody CR3022 expands cross-neutralization of SARS-CoV-2 variants and informs pan-sarbecovirus immunity - PubMed
4 hours ago
- #sarbecovirus immunity
- #antibody evolution
- #SARS-CoV-2
- CR3022 antibody's epitope is a promising target for broad protection against coronaviruses.
- A model using Ig-humanized mice shows CR3022 evolution through somatic hypermutation (SHM), enhancing affinity and breadth.
- SARS-CoV/SARS-CoV-2 sequential immunization leads to CR3022-like antibodies adapting to variants and sarbecoviruses.
- Intensive vaccination protocols shift immune responses away from CR3022-epitope targeting to other dominant epitopes.
- X-ray structures reveal CR3022-like antibodies increase affinity via polar and electrostatic interactions for better neutralization.